Loxo Oncology to Participate in Upcoming Investor Conferences
STAMFORD, Conn., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, today announced that company management will participate in fireside chats at the following upcoming investor conferences:
- Stifel Healthcare Conference in New York City on November 13, 2018 at 8:45 a.m. ET
- Piper Jaffray Healthcare Conference in New York City on November 28, 2018 at 10:30 a.m. ET
Live webcasts of the fireside chats will be available at .
About Loxo Oncology
Loxo Oncology is a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, with the intention of delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at .
Contacts for Loxo Oncology, Inc.
Company:
Lauren Cohen
Director, Corporate Communications
Investors:
Peter Rahmer
Endurance Advisors, LLC
415-515-9763
Media:
Dan Budwick
1AB Media
973-271-6085
